Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01YGD
|
|||
| Former ID |
DIB008118
|
|||
| Drug Name |
ICO-25
|
|||
| Synonyms |
Imuteran; Anti-MUC1 monoclonal antibodies, P Hertzen Moscow Cancer Research Institute; Anti-AG-4 antibodies, P Hertzen Moscow Cancer Research Institute
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Company |
Russian National Cancer Research Center
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mucin-1 (MUC1) | Target Info | . | [2] |
| WikiPathways | Hematopoietic Stem Cell Differentiation | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Atemonate and Imuteran: novel Russian monoclonal antibody-based therapeutic agents. Biotechnol J. 2007 Jul;2(7):863-70. | |||
| REF 2 | The role of epithelial antigens in diagnosis and staging of breast cancer. Arkh Patol. 2002 Nov-Dec;64(6):13-5. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.